Breast Cancer Now scientist's pioneering work is recognised as she joins membership of 1,700 of the best researchers in Europe and around the world.

Monday 19 June 2017      Research
""

Professor Clare Isacke

Breast Cancer Now is delighted to announce that Professor Clare Isacke, a leading researcher at the Breast Cancer Now Toby Robins Research Centre, is one of 65 life scientists elected to join the EMBO’s membership in recognition of outstanding research.

The European Molecular Biology Organisation (EMBO) promotes excellence in the life sciences, aiming to support talented researchers in all stages of their careers, stimulating the exchange of scientific information, and helping to build a collaborative and cohesive European research environment.

This recognition highlights Professor Isacke’s outstanding contribution to medical science, as well as the strength and diversity of European life sciences with the newly elected members residing in 21 countries.

Professor Isacke has been a key figure at the Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research (ICR) in London since 2001, when she was appointed as Professor of Molecular Biology. She has since been appointed to several senior roles, including Interim Director of the Division of Breast Cancer Research and is the current Academic Dean of the ICR.

Professor Isacke also leads the Molecular Cell Biology team at the Centre, whose research focuses on understanding how breast cancer cells interact with their surroundings to enable the cancer to spread to other sites in the body.

This process leads to the development of secondary breast cancer, which is currently incurable and claims the lives of almost 11,500 women every year in the UK. Professor Isacke’s work is therefore crucial to our ambition that, by 2050, everyone who develops breast cancer will live.

Dr Simon Vincent, Director of Research at Breast Cancer Now, said:

“We are thrilled to hear that Clare has been appointed as a member of EMBO. She has long been a key player in driving progress in secondary breast cancer research and her election to this prestigious organisation is further confirmation of the impact of her work.”